Crohn’s disease is a chronic inflammatory bowel illness that affects the gastrointestinal tract that affects primarily two age groups. The first is between the ages of 15 and 35, while the second is between the ages of 60 and 80.

The different pharmacological breakthroughs for Crohn’s disease treatment are proving advantageous to the market. Furthermore, changing lifestyles that have resulted in the replacement of healthy eating habits with unhealthy ones, as well as an increase in smoking, have resulted in an increase in the number of people diagnosed with Crohn’s disease, fueling further market expansion. In addition, rising demand for biologics to treat bowel disorders, such as Crohn’s disease, as well as increased awareness of the disease and potential therapies, are fuelling the market. On the other hand, the high cost of treatment is posing a hurdle to the industry. Furthermore, lack of early diagnosis, especially in developing countries, and the expiration of patents on blockbuster pharmaceuticals may stymie market progress in the near future.

The number of pipeline medications is expected to rise, accelerating growth. There are currently roughly 40 medications in the development, with five of them projected to hit the market in 2019. For example, Celgene Corporation’s mongersen (GED-0301) is currently through a phase III trial for Crohn’s disease and is set to market in 2019. In 2016, there were 27 biosimilars in development, with 11 of them in phase III studies.

Over the forecast period, the Asia Pacific market is expected to grow at a CAGR of 4.2%. Japan and China are thought to be the region’s most potential markets. Market growth is aided by dietary changes. This increase is mostly due to changes in eating habits, industrialization, and new disease diagnostic and treatment options. With the rising frequency of Crohn’s disease in the region, major companies in the industry consider Asia to be a lucrative market for Crohn’s disease. They are making big expenditures, which will most certainly boost the region’s market boom. Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 5.9 %, during the tenure of 2021 – 2027.

The report published by Maximize encompasses the market dynamics, which could affect the market growth of the Crohn’s Disease Therapeutics Market in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Crohn’s Disease Therapeutics Market at a global level. The study is associated based on major segments and further into sub-segments, Therapeutic Type (Single Dose Amino Acid Solution, Parenteral Lipid Emulsion) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2019, considering 2020 as the base year.

Lastly, the market research report provides a regional comparison and a complete country-level analysis for the Technology trends, along with the major key players- AbbVie Inc., Allergan, Inc., Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Co., GlaxoSmithKline plc, Janssen Biotech, Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company Limited.

You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Crohn’s Disease Therapeutics Market.”

https://www.maximizemarketresearch.com/market-report/crohns-disease-therapeutics-market/121644/ 

Contact:

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Office no. 4,

Navale IT Zone Phase-2,

Mumbai -Bangalore bypass highway,

Pune- 411041

Maharashtra, India

+91 9607195908

 

Leave a Replay

Your email address will not be published. Required fields are marked *

*
*